). Doses Administered in Doublets or Triplets Using the PSM-Matched Sample To estimate the possible effect of adding a third drug (anthracycline or docetaxel), oxaliplatin doses were compared in patients who received EOX (epirubicin, oxaliplatin, and
Search Results
Alberto Carmona-Bayonas, Paula Jiménez-Fonseca, Maria Luisa Sánchez Lorenzo, Avinash Ramchandani, Elena Asensio Martínez, Ana Custodio, Marcelo Garrido, Isabel Echavarría, Juana María Cano, Jose Enrique Lorenzo Barreto, Teresa García García, Felipe Álvarez Manceñido, Alejandra Lacalle, Marta Ferrer Cardona, Monserrat Mangas, Laura Visa, Elvira Buxó, Aitor Azkarate, Asunción Díaz-Serrano, Ana Fernández Montes, and Fernando Rivera
Al B. Benson III, J. Pablo Arnoletti, Tanios Bekaii-Saab, Emily Chan, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Raza A. Dilawari, Paul F. Engstrom, Peter C. Enzinger, James W. Fleshman Jr., Charles S. Fuchs, Jean L. Grem, James A. Knol, Lucille A. Leong, Edward Lin, Kilian Salerno May, Mary F. Mulcahy, Kate Murphy, Eric Rohren, David P. Ryan, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, William Small Jr., Constantinos T. Sofocleous, Alan P. Venook, and Christopher Willett
can be enrolled in a clinical trial, observed without adjuvant therapy, or considered for capecitabine or 5-FU/leucovorin (LV). Based on results of the MOSAIC trial, 83 – 86 and the possible long-term sequelae of oxaliplatin-based chemotherapy, the
Aparna Parikh, Chloe Atreya, W. Michael Korn, and Alan P. Venook
with capecitabine and oxaliplatin plus bevacizumab after 2 months with significant functional decline. Next-generation sequencing (NGS) of the primary tumor identified HER2 amplification and we were able to obtain trastuzumab-DM1 for off-label use
Quisette P. Janssen, Jacob L. van Dam, Laura R. Prakash, Deesje Doppenberg, Christopher H. Crane, Casper H.J. van Eijck, Susannah G. Ellsworth, William R. Jarnagin, Eileen M. O’Reilly, Alessandro Paniccia, Marsha Reyngold, Marc G. Besselink, Matthew H.G. Katz, Ching-Wei D. Tzeng, Amer H. Zureikat, Bas Groot Koerkamp, Alice C. Wei, and for the Trans-Atlantic Pancreatic Surgery (TAPS) Consortium
PREOPANC trial used gemcitabine alone, which was shown to be inferior to FOLFIRINOX (5-fluorouracil/leucovorin/irinotecan/oxaliplatin) in the metastatic and adjuvant setting. 11 , 12 Through extrapolation of these results, the NCCN Guidelines has included
Anurag Saraf, Hannah J. Roberts, Jennifer Y. Wo, and Aparna R. Parikh
tumors ( Figure 1 , Table 2 ). A phase II study by Fernández-Martos et al 23 investigated 108 patients with LARC randomized to SoC concurrent CAPOX (capecitabine/oxaliplatin) and RT, surgery, and adjuvant CAPOX versus TNT with CAPOX for 4 cycles
Angela Jain, Paula D. Ryan, and Michael V. Seiden
oxaliplatin (FOLFOX) with bevacizumab. Before the start of treatment, evaluation of tumor markers was notable for a carcinoembryonic antigen (CEA), alfa-feto-protein (AFP), and CA-125 levels of 644, 5149, and 16, respectively. After 6 treatments, CEA levels
Paul F. Engstrom
metastasis. Surveillance after successful resection of early-stage colon carcinoma consisted of periodic colonoscopy, physical examination, and serial carcinoembryonic antigen (CEA) determinations. Oxaliplatin was introduced as a therapeutic agent for colon
Zhi Ven Fong and Cristina R. Ferrone
horizon for patients with metastatic PDAC significantly changed with the multiagent chemotherapy regimens fluorouracil/folinic acid/irinotecan/oxaliplatin (FOLFIRINOX) 4 and gemcitabine/nab-paclitaxel, 5 respectively. Median survival for patients with
Ganessan Kichenadasse, John O. Miners, Arduino A. Mangoni, Christos S. Karapetis, Ashley M. Hopkins, and Michael J. Sorich
one of the fluoropyrimidines 5-FU or capecitabine. Fluoropyrimidine-based chemotherapy, given as either first-line or second-line therapy, included either irinotecan or oxaliplatin as part of multiagent combination therapy with fluoropyrimidines and
Esther N. Pijnappel, Willemieke P.M. Dijksterhuis, Lydia G. van der Geest, Judith de Vos-Geelen, Jan Willem B. de Groot, Marjolein Y.V. Homs, Geert-jan Creemers, Nadia Haj Mohammad, Marc G. Besselink, Hanneke W.M. van Laarhoven, Johanna W. Wilmink, and for the Dutch Pancreatic Cancer Group
treatment, 3 – 7 and progress in the development of new agents has been slow. Many cytotoxic agents in combination with gemcitabine did not show improvement in overall survival (OS) or quality of life (QoL). 3 – 5 , 8 – 12 In 2011, irinotecan/oxaliplatin/5
